AA
VERV

AQR Arbitrage’s Verve Therapeutics VERV Stock Holding History

AQR Arbitrage’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-208,700
Closed -$2.34M – 498
2025
Q2 		$2.34M Buy
+208,700
New +$1.19M 0.05% 209

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AQR Arbitrage's VERV Position: Q3 2025 in Review

AQR Arbitrage sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 208,700 shares — an estimated $2.34M sold.

AQR Arbitrage first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $2.34M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • AQR Arbitrage reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Arbitrage sold 208,700 Verve Therapeutics shares in Q3 2025, an estimated $2.34M.
  • AQR Arbitrage first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • AQR Arbitrage's Verve Therapeutics position peaked at $2.34M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on AQR Arbitrage's 13F filing for Q3 2025, filed 14 Nov 2025.